Skip to main content

CLS STOCK WRITE UP


CLS (CELESTICA)

  • P/E: 15.1
  • GAAP DILUTED EPS Y-O-Y GROWTH LAST QUARTER: $.14
  • SECTOR: ELECTRONIC TECHNOLOGY
  • ASSETS-LIABILITIES: 1.78
  • DIVIDEND: none

Celestica, a spinoff from IBM, manufactures electronics and provides supply chain services for a variety of businesses. The company has successfully improved upon its operating margins and revenue during its last fiscal year. Reporting April 20th before market open, the company will try to beat Wall street expectations of $.28 and its own guidance of $.24-$.3.
Celestica provides services for the communications, consumer, server, and storage industries, as well as working in diversified companies. This wide array of services gives Celestica the opportunity to expand on revenue when one of its segments is lagging. Rather than developing new products to boost revenue, Celestica must rely on increasing customer satisfaction by managing supply chains well for its clients. In order to showcase their services, the company recently built a new customer service center where clients can interact with agents observe demonstrations of Celestica's services. The company's supply chain management business is a product of its own journey to establishing a successful in-house contract manufacturing process. Therefore, its supply chain management not only boosts revenue organically, but it improves the company's manufacturing business, as well. The company sells design and engineering services, manufacturing, logistics, after-market, supply chain services, and precision machining to its clients.
The company's CEO, Rob Mionis, has a wealth of experience, having held the same title with StandardAero, and other high-ranking positions with Honeywell, and private equity. The company saw slight reduction in its free cash flow in FY 2016, but its operating margin, revenues, and assets-liabilities ratios all improved. The only recent change to the core company's leadership is the addition of Thomas Gross, former COO of the electrical sector of energy giant Eaton.
With a low P/E, recent growth, and a solid balance sheet, the company could grow without becoming overvalued. Earnings expectations from both wall street and the company would not buck the current trend if surpassed. The company has 4 “buy” and 8 “hold” ratings, according to the Wall Street Journal.

SOURCES:






Labels:

Comments

Post a Comment

Popular posts from this blog

ISRG STOCK WRITE UP

ISRG (INTUITIVE SURGICAL INC) P/E: 48 GAAP DILUTED YEAR-OVER-YEAR EPS GROWTH LAST QUARTER: $1.13 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 7.05 DIVIDEND: none ISRG is the ticker for Intuitive Surgical Inc, a company endeavoring in the manufacture and distribution of robotic surgical devices. The company recently gained FDA approval for a lower-cost device. They have a clean balance sheet with a history of upside surprises against earnings expectations, and report again 7/20/17. Revenues increased nearly 14%, while EPS increased 32% compared to the Q1 '16 results. While liabilities decreased on a year-over-year basis, assets decreased by a larger margin. R&D spending increased 36%, and administrative costs rose 16%. Taxes were cut in half, although the revenues increased, due to modified accounting principles, and tax benefits for the employee share-based compensation.. The ratio of assets-liabilities decreased from 9.14 to 7.05, which is...
1 comment
Read more

AMGN STOCK WRITE UP

AMGN P/E: 16.1 GAAP EPS Y-O-Y GROWTH LAST QUARTER: $.22 SECTOR: HEALTH TECHNOLOGY ASSETS-LIABILITIES: 1.62 DIVIDEND: 2.54% Amgen is a leading biotech company with a solid financial foundation. It has managed to reduce its spending on research and development while increasing revenue through its sales of established drugs such as Enbrel, and Prolia. The company has several rapidly growing drugs that are newer to the market, with many drugs in the company's pipeline. In its last quarter, Amgen posted 7.7% revenue growth with 7.5% net income growth. The company spent less, however, in the most recent quarter when compared with the comparable quarter from the prior year, on research and development. The reduction in operating margin came from an increased interest expense in the quarter. Although the company spent less on research and development, its revenue did increase. Amgen is continuing to innovate despite reduced research and development b...
Post a Comment
Read more

PXD STOCK WRITE UP

 PXD (PIONEER NATURAL RESOURCES) P/E: N/A GAAP DILUTED Y-O-Y EPS GROWTH LAST QUARTER: $.67 SECTOR: ENERGY MINERALS ASSETS-LIABILITIES: 1.58 DIVIDEND: .04% Pioneer Natural Resources has recently made the jaw-dropping switch from negative EPS to positive with its last quarter. Situated in the largest oil-producing region in the US, the company is utilizing its good fortune to produce profits. The company has a good balance sheet, a wealth of resources, and a business model which has afforded it growth. This last quarter does not mark the first occasion on which Pioneer has posted a profit. In 2014, and 2012, Pioneer posted a positive EPS for the full year. While the 2016 oil and gas revenues have grown from 2015, the 2014 and 2012 levels were higher. The company's revenue from oil and gas is largely based on market prices. In order to mitigate the market volatility, Pioneer has made efforts to reduce their cost of production, according to their earnin...
1 comment
Read more